Development of a Human Cerebrovascular Model To Study Alzheimer’s Disease in vitro

21 juin 2018

Auditorium, local 2458
Hôpital et centre d’hébergement D’Youville

Disponible en visioconférence à 11 h 50 (réservez tôt)

Présentation en anglais

Alzheimer’s Disease (AD) is the leading cause of senile dementia with over 44 million affected persons and an economic burden of over $600 billion. Amyloid plaques, consisting of deposited beta-amyloid, and neurofibrillary tangles consisting of hyperphosphorylated tau proteins are neuropathological hallmarks of Alzheimer’s Disease. As cardiovascular risk factors increase dementia risk, major pathways that regulate beta-amyloid clearance from the brain involve the cerebrovasculature, and most AD patients have vascular amyloid deposition (cerebral amyloid angiopathy (CAA)), it is now clear that cerebral vessels play a major role in AD pathogenesis.

Jérôme Robert will present a novel human experimental platform to investigate the cerebrovascular contribution to AD, in which three dimensional perfusible cerebral blood vessels are engineered in a scaffold-directed flow bioreactor system from primary human endothelial cells (EC) and smooth muscle cells (SMC), with or without astrocytes.

Plus d'activités